| Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine LT Geller, M Barzily-Rokni, T Danino, OH Jonas, N Shental, D Nejman, ... Science 357 (6356), 1156-1160, 2017 | 1481 | 2017 |
| Tumor microbiome diversity and composition influence pancreatic cancer outcomes E Riquelme, Y Zhang, L Zhang, M Montiel, M Zoltan, W Dong, P Quesada, ... Cell 178 (4), 795-806. e12, 2019 | 1168 | 2019 |
| Borderline resectable pancreatic cancer: the importance of this emerging stage of disease MHG Katz, PWT Pisters, DB Evans, CC Sun, JE Lee, JB Fleming, ... Journal of the American College of Surgeons 206 (5), 833-846, 2008 | 945 | 2008 |
| International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017 S Isaji, S Mizuno, JA Windsor, C Bassi, C Fernández-del Castillo, ... Pancreatology 18 (1), 2-11, 2018 | 690 | 2018 |
| Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study COVIDSurg Collaborative Anaesthesia 76 (6), 748-758, 2021 | 589* | 2021 |
| Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators MHG Katz, JB Fleming, P Bhosale, G Varadhachary, JE Lee, R Wolff, ... Cancer 118 (23), 5749-5756, 2012 | 559 | 2012 |
| Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma MHG Katz, H Wang, JB Fleming, CC Sun, RF Hwang, RA Wolff, ... Annals of surgical oncology 16, 836-847, 2009 | 559 | 2009 |
| High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients K Allenson, J Castillo, FA San Lucas, G Scelo, DU Kim, V Bernard, ... Annals of Oncology 28 (4), 741-747, 2017 | 485 | 2017 |
| Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology … MHG Katz, Q Shi, SA Ahmad, JM Herman, RW Marsh, E Collisson, ... JAMA surgery 151 (8), e161137-e161137, 2016 | 459 | 2016 |
| Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline AA Khorana, PB Mangu, J Berlin, A Engebretson, TS Hong, A Maitra, ... Journal of Clinical Oncology 34 (21), 2541-2556, 2016 | 431 | 2016 |
| Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline RT Shroff, EB Kennedy, M Bachini, T Bekaii-Saab, C Crane, J Edeline, ... Journal of Clinical Oncology 37 (12), 1015-1027, 2019 | 421 | 2019 |
| Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design MHG Katz, R Marsh, JM Herman, Q Shi, E Collison, AP Venook, ... Annals of surgical oncology 20, 2787-2795, 2013 | 372 | 2013 |
| Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer V Bernard, DU Kim, FA San Lucas, J Castillo, K Allenson, FC Mulu, ... Gastroenterology 156 (1), 108-118. e4, 2019 | 355 | 2019 |
| Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation S Krishnan, AS Chadha, Y Suh, HC Chen, A Rao, P Das, BD Minsky, ... International Journal of Radiation Oncology* Biology* Physics 94 (4), 755-765, 2016 | 349 | 2016 |
| Nanoplasmonic quantification of tumour-derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring K Liang, F Liu, J Fan, D Sun, C Liu, CJ Lyon, DW Bernard, Y Li, K Yokoi, ... Nature biomedical engineering 1 (4), 0021, 2017 | 338 | 2017 |
| Single-cell transcriptomics of pancreatic cancer precursors demonstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression V Bernard, A Semaan, J Huang, FA San Lucas, FC Mulu, BM Stephens, ... Clinical Cancer Research 25 (7), 2194-2205, 2019 | 329 | 2019 |
| Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis QP Janssen, S Buettner, M Suker, BR Beumer, P Addeo, P Bachellier, ... JNCI: Journal of the National Cancer Institute 111 (8), 782-794, 2019 | 319 | 2019 |
| Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer J Blando, A Sharma, MG Higa, H Zhao, L Vence, SS Yadav, J Kim, ... Proceedings of the National Academy of Sciences 116 (5), 1692-1697, 2019 | 312 | 2019 |
| Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline update AA Khorana, PB Mangu, J Berlin, A Engebretson, TS Hong, A Maitra, ... Journal of Clinical Oncology 35 (20), 2324-2328, 2017 | 265 | 2017 |
| Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome D Chatterjee, MH Katz, A Rashid, GR Varadhachary, RA Wolff, H Wang, ... Cancer 118 (12), 3182-3190, 2012 | 257 | 2012 |
Jeffrey E LeeProfessor of Surgery, University of Texas MD Anderson Cancer CenterVerified email at mdanderson.org
